logo-loader

Akero Therapeutics stock tanks after NASH liver treatment study disappoints

Published: 11:48 10 Oct 2023 EDT

Liver graphic

Akero Therapeutics Inc shares lost roughly two-thirds of their value Tuesday morning after the company released a disappointing update on its fatty liver disease treatment. 

A study found that just 22% to 24% of the patients with compensated cirrhosis due to NASH (nonalcoholic steatohepatitis) who received Akero’s treatment efruxifermin saw at least a one-stage improvement in liver fibrosis, according to a statement. 

Shares of Akero plummeted 68% to $15.57. 

On the positive side, roughly 60% of patients who received efruxifermin had NASH resolution after 36 weeks, compared with 26% of those who received a placebo.

That represents, “the highest response rates reported to date for NASH resolution in this patient population,” the company said.

“We set a high bar with the primary endpoint after only 36 weeks of treatment,” CEO Andrew Cheng said in a statement. But efruxifermin “has the potential to show additional improvements for patients after the long-term follow-up period is complete” at week 96, he added.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Scancell CEO on FDA breakthrough, melanoma survival data and Phase 3 plans

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) CEO Phillip L’Huillier talked with Proactive's Stephen Gunnion about the company's latest clinical and regulatory progress, including FDA RMAT designation for its lead melanoma treatment, inzitagene plasmivec (iSCIB1+), updated survival data and...

2 hours, 40 minutes ago